Radiation therapy for liver cancer that progresses after first immunotherapy
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding targeted radiation to liver cancer patients who have limited progression after initial immunotherapy can help control the disease. It is for people with hepatocellular carcinoma (HCC) whose cancer has started to grow in just a few spots after their first PD-1 treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed liver cancer diagnosis (by biopsy or imaging).
- Your cancer must have started to grow in 5 or fewer spots and in 3 or fewer organs after your first immunotherapy (PD-1 blocker).
- You should have had stable disease for at least 3 months while on that immunotherapy.
- Your overall health must be good enough for daily activities (ECOG 0 or 1).
- You cannot have had radiation therapy before for your liver cancer.
- You must be between 18 and 75 years old and willing to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests whether giving radiation to a few growing cancer spots while continuing your current treatment works better than switching to a new treatment right away. It's for people whose advanced liver cancer has only barely started to progress on their first therapy.
This trial tests a combination of radiation therapy, an immunotherapy drug (tislelizumab), and a targeted therapy drug (anlotinib) for people with liver cancer that has spread into the main vein of the liver. It is for patients who have not had any prior treatment for their liver cancer.
This trial tests whether a targeted radiation therapy (SBRT) can help people with liver cancer whose disease has only a few new spots growing while on first-line immunotherapy. It aims to see if zapping those spots can control the cancer and delay the need for stronger treatments.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This trial tests whether using immunotherapy alone works as well as immunotherapy combined with radiation for liver cancer that has spread into major blood vessels. The goal is to find the best treatment option for people with this specific type of advanced liver cancer.
Hear when a new Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.